Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfizer/BioNTech or Moderna booster in high-risk individuals
NCT05279365Phase 3Unknown
- Sponsor
- DHR Health
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19), sponsored by DHR Health. Primary endpoints: Number of participants infected with SARS-CoV-2 after booster Dose at 24 months and Levels of anti-SARS-CoV-2 IgG antibody titers after booster at 24 months. Status: unknown.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05279365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279365.